Mark Pollack to Randomized Controlled Trials as Topic
This is a "connection" page, showing publications Mark Pollack has written about Randomized Controlled Trials as Topic.
Connection Strength
0.426
-
Tiagabine in adult patients with generalized anxiety disorder: results from 3 randomized, double-blind, placebo-controlled, parallel-group studies. J Clin Psychopharmacol. 2008 Jun; 28(3):308-16.
Score: 0.069
-
Examining quality of life in patients with generalized anxiety disorder: clinical relevance and response to duloxetine treatment. J Psychiatr Res. 2008 Oct; 42(12):1042-9.
Score: 0.067
-
The pharmacotherapy of panic disorder. J Clin Psychiatry. 2005; 66 Suppl 4:23-7.
Score: 0.054
-
Predictors of outcome following venlafaxine extended-release treatment of DSM-IV generalized anxiety disorder: a pooled analysis of short- and long-term studies. J Clin Psychopharmacol. 2003 Jun; 23(3):250-9.
Score: 0.048
-
Early improvement predicts endpoint remission status in sertraline and placebo treatments of panic disorder. J Psychiatr Res. 2002 Jul-Aug; 36(4):229-36.
Score: 0.046
-
An effect-size analysis of the relative efficacy and tolerability of serotonin selective reuptake inhibitors for panic disorder. Am J Psychiatry. 2001 Dec; 158(12):1989-92.
Score: 0.044
-
Do antidepressants selectively suppress spontaneous (unexpected) panic attacks? A replication. J Clin Psychopharmacol. 2000 Dec; 20(6):622-7.
Score: 0.041
-
Sertraline treatment of panic disorder: response in patients at risk for poor outcome. J Clin Psychiatry. 2000 Dec; 61(12):922-7.
Score: 0.041
-
Efficacy and tolerability of duloxetine in elderly patients with generalized anxiety disorder: a pooled analysis of four randomized, double-blind, placebo-controlled studies. Hum Psychopharmacol. 2008 Aug; 23(6):519-26.
Score: 0.017